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ABSTRACT
Introduction The introduction of the faecal calprotectin 
(FC) test to screen children with chronic gastrointestinal 
complaints has helped the clinician to decide whether or 
not to subject the patient to endoscopy. In spite of this, 
a considerable number of patients without inflammatory 
bowel disease (IBD) is still scoped. Faecal calgranulin 
C (S100A12) is a marker of intestinal inflammation 
that is potentially more specific for IBD than FC, as it is 
exclusively released by activated granulocytes.
Objective To determine whether the specificity of 
S100A12 is superior to the specificity of FC without 
sacrificing sensitivity in patients with suspected IBD.
Methods An international prospective cohort of children 
with suspected IBD will be screened with the existing FC 
stool test and the new S100A12 stool test. The reference 
standard (endoscopy with biopsies) will be applied to 
patients at high risk of IBD, while a secondary reference 
(clinical follow-up) will be applied to those at low risk of 
IBD. The differences in specificity and sensitivity between 
the two markers will be calculated.
Ethics and dissemination This study is submitted to and 
approved by the Medical Ethics Review Committee of the 
University Medical Center Groningen (the Netherlands) 
and the Antwerp University Hospital (Belgium). The 
results will be disseminated through a peer-reviewed 
publication, conference presentation and incorporation in 
the upcoming National Guideline on Diagnosis and Therapy 
of IBD in Children.




The introduction of the calprotectin stool 
test to screen children with chronic gastroin-
testinal complaints has helped the clinician 
to decide whether or not to refer the patient 
for endoscopy.1–4 We have shown that chil-
dren with normal screening test results 
(≤50 µg/g) have a low probability of inflam-
matory bowel disease (IBD) and should 
therefore not undergo the invasive reference 
test (endoscopy) to exclude IBD.5 Children 
with elevated calprotectin levels, however, 
have a high probability of IBD and require 
referral to an endoscopy unit for endoscopic 
evaluation of upper and lower gastrointestinal 
tract.1 4 5 Although use of the calprotectin 
stool test rarely misses a child with IBD, the 
number of false positive cases who are scoped 
is considerable.1 5 Calprotectin is a member 
of the S100 calcium-binding protein family 
and is a heterodimer of S100A8 and S100A9. 
The protein is released mainly by neutrophil 
granulocytes, and also by other activated and 
damaged cells including monocytes, macro-
phages and epithelial cells.6 7 Calgranulin C 
(S100A12) is a less investigated member of 
the S100 protein family.7 8 Since S100A12 is 
only released by activated granulocytes, it is 
suggested to be more specific for gastroin-
testinal inflammation caused by IBD than 
calprotectin.7 9–11
objectives
We hypothesise that a referral strategy based 
on faecal S100A12 will reduce the number 
Strengths and limitations of this study
 ► Prospective multicentre study evaluating the 
diagnostic accuracy of a new faecal marker 
(S100A12) with respect to the currently used 
faecal marker (calprotectin) to select children with 
gastrointestinal complaints for endoscopy.
 ► Our study design reflects current clinical practice in 
the Netherlands and Belgium.
 ► Due to the invasive nature of the preferred reference 
standard (endoscopy) we used clinical follow-up as 
alternative reference test.
 ► A limitation of the use of two reference standards 
is the introduction of a differential verification bias.
 ► We present a Bayesian approach to deal with the 
introduced differential verification bias.
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of children wrongly selected for endoscopy as compared 
with a calprotectin-based strategy. The primary objective 
is to determine whether the specificity of S100A12 is supe-
rior to the specificity of calprotectin without sacrificing 
sensitivity. The secondary objective is to calculate the 
diagnostic accuracy characteristics and best cut-offs for 
both S100A12 and calprotectin.
MeThods
design
The CACATU (Calprotectin or Calgranulin C test before 
undergoing endoscopy) study is a prospective, obser-
vational, multicentre, diagnostic accuracy study with a 
paired design. A cohort of children with suspected IBD 
is screened with the calprotectin stool test (existing test) 
and with the S100A12 stool test (new test). Confirma-
tion of the target condition (IBD) is based on endoscopy 
with biopsies (reference standard) or clinical follow-up 
(secondary reference standard).
study setting
Study participants will be recruited from 15 general 
teaching hospitals and one academic centre in the Neth-
erlands and from one general hospital and two academic 
centres in Flanders, Belgium. The names of all partic-
ipating centres can be found in the trial registry (www. 
clinicaltrials. gov). The principal investigators at the 
various sites are general paediatricians or paediatric 
gastroenterologists. Six participating centres (three 
academic and three general hospitals) have a paediatric 
endoscopy unit.
eligibility criteria
Patients were eligible if they were between 6 and 17 years 
old and presented with at least one major criterion or two 
minor criteria suggestive of IBD (box 1).
outcomes
The primary outcome is the difference in speci-
ficity between faecal calprotectin (FC) and S100A12. 
Secondary endpoints are the difference in sensitivity and 
the diagnostic accuracy characteristics (sensitivity, speci-
ficity, positive predictive value, negative predictive value, 
area under the curve, best cut-off point) for both markers 
individually. All diagnostic accuracy characteristics will 
be calculated with predefined cut-off points that have 
been documented in the medical literature, and with best 
cut-off points based on receiver operating characteristic 
(ROC) curves.
Intervention
Patients who fulfil the inclusion criteria will be risk strat-
ified (high vs low risk of IBD) according to presenting 
symptoms, blood tests and stool calprotectin (figure 1). 
In general, we expect that those participants with 
increased calprotectin levels (> 50 µg/g) without colon 
pathogens are likely to be referred to endoscopy (the 
preferred reference standard) to confirm or exclude 
IBD. Patients with a normal stool calprotectin test level 
are likely to have a low probability of IBD and will be 
followed clinically to determine the final diagnosis (the 
alternative reference standard), unless there will be 
other indications to scope them. Paediatricians will be 
free to use any diagnostic test, such as coeliac disease 
screening, breath test or ultrasonography (whichever is 
deemed suitable).
Participant study flow
Eligible participants will be invited for participation by 
the attending paediatrician. Baseline characteristics, 
date of birth, major and minor criteria (box 1), use 
of non-steroidal anti-inflammatory drugs and blood 
tests (haemoglobin, C reactive protein, erythrocyte 
sedimentation rate, serum alanine transaminase and 
gamma-glutamyltransferase) will be entered on a study 
website (figure 2, step 1). Participants will be asked to 
defecate onto a stool collection sheet held above the 
toilet water and collect one sample with a screw-top 
container with spoon (step 2). The stool sample is sent 
to the Department of Laboratory Medicine of the Univer-
sity Medical Center Groningen (UMCG) in a biomaterial 
envelope. Immediately after arrival, the stool calprotectin 
level will be measured. The residue will be split with 
one-half stored at −80°C for S100A12 batch testing at a 
later stage, and the other half will be used to determine 
enteric pathogens with a PCR technique (step 3). The 
PCR analysis will include Shiga toxin-producing Esche-
richia coli, E. coli O157gen, Cryptosporidium, Dientamoeba 
fragilis, Entamoeba histolytica, Giardia lamblia, Salmonella, 
Shigella/Enteroinvasive E. coli and Campylobacter. Results 
of calprotectin test and PCR analysis will be uploaded 
to the website, and will then be made visible to the local 
clinician (steps 4 and 5). The paediatrician will receive an 
email notification with an automated advice on the next 
best move (step 6). However, the choice of the reference 
Box 1 Study inclusion criteria (one major criterion or two 
minor criteria are required to make the patient eligible for 
participation in the CACATU study)
Major criteria
 ► Persistent diarrhoea for more than 4 weeks
 ► Recurrent abdominal pain with diarrhoea with at least two episodes 
in the previous 6 months
 ► Rectal blood loss
 ► Perianal disease (fistula, deep fissure, abscess)
Minor criteria
 ► Involuntary weight loss
 ► First-degree family member with inflammatory bowel disease
 ► Anaemia (haemoglobin <2 SD for age and gender)
 ► Increased marker of inflammation (erythrocyte sedimentation rate 
>20 mm/hour or C reactive protein >10 mg/L)
 ► Extraintestinal symptoms (erythema nodosum, arthritis, uveitis, 
thromboembolism, aphthous ulcers)
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Figure 1 CACATU study flow. IBD, inflammatory bowel disease.
group.bmj.com on September 1, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Heida A, et al. BMJ Open 2017;7:e015636. doi:10.1136/bmjopen-2016-015636
Open Access 
standard (endoscopy or clinical follow-up) is up to the 
paediatrician’s discretion (step 7).
Timeline
The process from faeces collection to completion of the 
non-invasive diagnostic work-up is supposed to last no longer 
than 2 weeks. We will exclude samples with a transport time 
that exceeds 7 days and we will perform a subanalysis with 
those samples that are received within 4 days. In case of 
low risk of relapse, the treating paediatricians will receive 
a reminder for clinical follow-up 6 months after inclusion. 
Figure 2 CACATU study flow from first hospital visit to choice of reference test. Step 1: The clinician registers the patient on 
the study website (www.cacatustudie.eu). Step 2: The patient (or parent) collects the stool specimen and sends it to the hospital 
laboratory. Step 3: The lab divides the specimen into three portions: calprotectin and PCR are immediately performed; one 
tube is stored at −80°C for calgranulin C testing. Step 4: The lab sends the results of calprotectin and PCR to the researcher. 
Step 5: The researcher enters the test results on the website. Step 6: The clinician receives a notification with the results and 
an automated advice on the next best move. Step 7: Paediatrician decides the next best move: in case of high probability of 
inflammatory bowel disease (IBD): endoscopy; in case of low probability of IBD: clinical follow-up. The ultimate decision to 
scope is in the hands of the endoscopist. FC, faecal calprotectin; UMCG, University Medical Center Groningen.
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The total running time of the study is 30 months, including 
6 months to complete the follow-up.
sample size
The primary outcome of interest is the difference in 
specificity between the new test (S100A12) and the estab-
lished test (FC). If the specificity of S100A12 is superior 
to the specificity of FC without sacrificing sensitivity, 
we can replace the old test by the new test. McNemar’s 
test for paired data will be applied to compare speci-
ficities between both tests using a 2×2 table exclusively 
among non-IBD patients (table 1). Study participants 
with concordant results ((+, +) or (−, −)) do not distin-
guish between the two tests. The only information for 
comparing the sensitivities and specificities comes from 
those patients with discordant results ((+, −) or (−, +)). 
Sample size calculation is based on recommendations in 
Hayen et al.12 Weighed means of specificity of calprotectin 
were based on a recently published individual patient 
data meta-analysis.4 We assumed that faecal S100A12 
would lead to a 50% relative improvement of specificity 
(from 70% to 85%). The prevalence of IBD and non-IBD 
in the CACATU study cohort is expected to be similar to 
the prevalence that we found earlier,1 as the study partic-
ipants will come from the same region and comparable 
eligibility criteria will apply. The sample size calculation 
was done with Power Analysis and Sample Size software 
(version 11 for Windows). A sample size of 130 subjects 
with non-IBD achieves 80% power to detect a difference 
of 0.15 between the two diagnostic tests whose specifici-
ties are 0.70 and 0.85. This procedure used a two-sided 
McNemar test with a significance level of 0.05. The prev-
alence of non-IBD in the population is 0.64, and the 
proportion of discordant pairs is 0.23. We aim to include 
at least 250 participants in order to correct for participants 
diagnosed with IBD (estimated 36%) and participants 
that will be lost to follow-up (estimated 25%).
recruitment
We asked all participating centres to predict how many 
eligible patients they could recruit during the enrolment 
period. Their estimates were based on the list of diagnoses 
of the previous year, and their estimated totals convinced 
us that reaching the target sample size is realistic. Reten-
tion will be promoted by sending automated reminders 
to the treating physician to complete the blanks in blood 
tests, and to reassess patients with initial low probability of 




FC levels will be measured with the fCal ELISA test of 
BÜHLMANN Laboratories AG (Schönenbuch, Switzer-
land) according to the manufacturer’s instructions. A 
level of 50 µg/g is the predefined cut-off value.2 4 5 13
Faecal calgranulin C (S100A12)
S100A12 levels will be measured by one experienced labo-
ratory technician. The maximal duration of storage of 
the stool sample in our −80°C freezer is 6 months. Anal-
yses will be performed with a sandwich ELISA, trademark 
Inflamark (CisBio Bioassays, Codolet, France) on a Dynex 
DS2 Automated ELISA System (Alpha Labs, Easleigh, UK), 
according to the manufacturers’ instructions. In summary, 
after extraction step, 100 µL of prediluted samples will be 
transferred in duplicate into the corresponding wells coated 
with anti-S100A12 monoclonal antibody. Incubation time 
is 30 min, followed by three washing cycles with Tween 20. 
The next step is adding 100 µL of the second monoclonal 
antibody, anti S100A12 coupled to horseradish peroxidase 
followed by a second incubation period of 30 min and three 
washing cycles. Next, 100 µL of the substrate, tetramethyl-
benzidine, is pipetted in all wells. The wells are protected 
from light and after 10 min, the sulfuric acid stop solution 







Positive Concordant (v) Discordant (w) v+w
Negative Discordant (x) Concordant (y) x+y





Positive Concordant (r) Discordant (s) r+s
Negative Discordant (t) Concordant (u) t+u
Total r+t s+u N+
Null hypothesis H0 (specificity): w=x; alternative hypothesis H1: w≠x.
Null hypothesis H0 (sensitivity): s=t; alternative hypothesis H1: s≠t.
IBD, inflammatory bowel disease.
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is added. The absorbance will be read at 450 nm. For each 
duplicate, the mean optical density will be calculated and 
a calibration curve will be constructed. The curve will 
be plotted as a cubic regression with DS-matrix software, 
version 1.23 (Dynex technologies, Chantilly, USA). Purified 
human S100A12 will be used as calibrator (included in the 
kit).
The predefined cut-off value of S100A12 is 0.75 mg/
kg, which is based on a reference value study among 120 
healthy school-aged children and adolescents .14
reference tests
Endoscopy
Endoscopy will be the reference standard for patients at 
high risk of IBD. This procedure will be performed under 
anaesthesia by an experienced paediatric gastroenterol-
ogist. Ideally, both upper and lower gastrointestinal tract 
will be evaluated according to the revised Porto criteria,15 
and biopsies will be taken from every bowel segment. Histo-
pathological examination will be performed by experienced 
histopathologists. Endoscopists and histopathologists will 
have access to clinical information and FC test results, but 
will be blinded to the results of the S100A12 test.
Clinical follow-up
This secondary reference will be applied to patients at 
low risk of IBD. Six months after study inclusion, the 
treating paediatrician will receive a notification to enter 
a second evaluation of major and minor criteria (box 1). 
Blood tests will only be repeated when deemed neces-
sary by the treating paediatrician. In addition, a second 
faeces sample will be collected and sent in for analysis. 
Patients who remain suspected of having IBD will be 
referred for further investigations in second instance. At 
study closure, one of the researchers (AH) will visit the 
participating centres to cross-check patient records for 
the definite diagnosis.
rationale for choosing reference standard
Diagnostic endoscopic evaluation of the upper and lower 
gastrointestinal tract (including intubation of the terminal 
ileum) in combination with biopsies is the recommended 
test to diagnose IBD.15 In children at high risk of IBD 
with negative endoscopy, small bowel imaging is encour-
aged.15 All of these procedures are invasive and require 
bowel preparation. Endoscopy is mostly performed with 
the patient under general anaesthesia. Although compli-
cations are rare, endoscopy is a burdensome procedure 
for a child. We found it unethical to expose children 
at low risk of IBD to endoscopy. Therefore, we decided 
to perform a secondary reference standard (clinical 
follow-up) in patients at low risk for IBD and to adjust for 
its imperfection.16
Blinding
Laboratory personnel will be blinded to the patient’s 
history, and to the results of endoscopy and biopsy. 
Although calprotectin testing is done within 24 hours 
after arrival of the faeces specimen and the residue is 
stored at −80°C for S100A12 batch testing at a later stage, 
sample labelling could theoretically link both faecal tests 
to one patient. Endoscopists and histopathologists will 
have access to clinical information and calprotectin test 
results, but will be blinded to the results of the S100A12 
test.
confidentiality and data management
Consecutive patients participating in the study will receive 
a unique study number. All demographic and medical data 
will be entered electronically on the study website by the 
local investigator and stored linked to this study number. 
Study investigators will receive access to a secured study 
website. Local investigators are able to consult only data 
from participants from their own centre. Faeces samples 
will be marked with a study number label and sent to 
the Department of Laboratory Medicine at the UMCG. 
Results of calprotectin test and PCR for enteric pathogens 
will be uploaded to the website by the coordinating inves-
tigator and will be visible to the local clinician. At the end 
of the study, the data entered on the study website will 
be cross-checked with the information in the local Elec-
tronic Health Databases. Data will be stored during the 
study period and until 15 years thereafter. When patients 
and their parents give permission, residual faeces will be 
stored for a maximum period of 15 years for future diag-
nostic research. The researchers AH, EvdV and PvR will 
have access to the final trial dataset.
statistical methods
Data analysis will be done with SPSS V.22.0 for Windows 
(SPSS, Chicago, Illinois, USA). Diagnostic accuracy char-
acteristics (sensitivity, specificity, positive predictive value, 
negative predictive value) will be presented for both 
markers individually. We will primarily use prespecified 
cut-off points of FC and S100A12. In the second instance, 
we will use the best cut-off points based on the ROC 
curves for both FC and S100A12.
We will use a Bayesian correction method to adjust for 
differential verification bias in the two reference standards 
in relation to latent IBD.17 Based on clinical experience, 
we defined a prior distribution. We assume that our 
reference standard endoscopy has 95%–100% sensitivity 
and 95%–100% specificity to diagnose IBD, and that our 
secondary reference standard clinical follow-up will have 
a sensitivity of 80%–100% and a specificity of 60%–80%. 
Bayes factors will be calculated using JAGS (‘Just Another 
Gibbs Sampler’), a free program licensed under GNU 
General Public License.
Missing values
In case the index test and reference standard results are 
missing, the patient will be excluded from further analysis.
ethical approval and dissemination policy
The study will be conducted according to the principles 
of the Declaration of Helsinki (59th version, October 
2008). The Medical Ethics Review Committee (MEC) of 
the UMCG is of the opinion that this study does not 
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require approval according to the Dutch Medical Research 
Involving Human Subject Act (WMO). The MEC of the 
Antwerp University Hospital approved the protocol. The 
legal guardian(s) of all participants, as well as children aged 
12 and above, will need to give informed consent for partic-
ipation and for storage of material for future research.
In case of important protocol amendments, both the 
MEC and trial registry will be informed. The results of the 
trial will be disseminated through a peer-reviewed publi-
cation, conference presentation and incorporation in the 
upcoming National Guideline on Diagnosis and Therapy 
of IBD in Children.
study status
The first trial participant was included in September 2014. 
It is anticipated that the trial will end in the spring of 2017.
dIscussIon
We aim to further improve the accuracy to distinguish 
patients with a high risk of IBD from those with a low risk 
of IBD with the ultimate goal to reduce the number of 
futile endoscopies. We will compare the established 
faecal marker FC with the relatively unknown faecal 
marker S100A12. The FC test has excellent sensitivity 
for IBD (0.92–0.98),2–4 18 but its specificity, with point 
estimates varying between 0.60 and 0.68,2–4 18 leaves a 
considerable proportion of non-IBD patients being 
exposed to an invasive procedure. Studies with faecal 
S100A12 showed diagnostic promise under ideal testing 
conditions in preselected groups of healthy children 
and children with IBD.9 11 19 We only know of one report 
that compared FC and S100A12 in children presenting 
with gastrointestinal complaints.11 The sensitivity and 
specificity of S100A12 for detection of IBD were both 
97%, where FC had a sensitivity of 100% and a speci-
ficity of 67%.11
Methodological biases
In this diagnostic accuracy study, the performance of 
both stool tests will be assessed by verifying the results 
against endoscopy. Due to the invasive nature of this diag-
nostic procedure, verification can be performed only in 
a subset of patients with a high risk of IBD. An alternative 
reference test (ie, clinical follow-up) will be used in the 
remainder of the patients. The drawback of this so-called 
differential verification design is that the second refer-
ence test is of lesser quality. Simply adding the results of 
these two types of reference tests will lead to biased esti-
mates of the overall test accuracy.16 We plan to correct 
for this differential verification bias by using a Bayesian 
approach, as described by De Groot et al.17Second, this 
study is a real-life study, in which the decision to expose 
a child to endoscopy is based on the combination of 
presenting symptoms, physical examination and results 
of blood and stool tests, as is currently recommended 
by Dutch and international scientific societies. Blinding 
treating physicians for the FC results was therefore irra-
tional and impractical. Knowledge of the FC level will 
influence the physicians’ decision to refer a patient for 
endoscopic evaluation, which gives rise to a work-up 
bias.20 Furthermore, endoscopists will not be blinded for 
the level of FC and therefore this may theoretically affect 
the endoscopists’ assessment of the endoscopy (diag-
nostic review bias).
Implications for practice
If S100A12 has a better specificity than FC without 
sacrificing sensitivity, than S100A12 will be the domi-
nant test to select patients for endoscopy. Replacing FC 
by S100A12 may then reduce the number of non-IBD 
patients being subjected to endoscopy. This will be 
good news for patients (less invasive tests), clinicians 
(shorter waiting lists for endoscopy) and health insur-
ance companies (reduction of healthcare costs).
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